Experienced team with world class expertise

The Regulonix team has world-class expertise in ion-channel biology, pain channel research and drug delivery technology.

Developing a pipeline of indirectly targeted drugs will result in new, non-opioid treatments for a number of significant unmet medical conditions, including neuropathic pain and pain due to neurodegenerative conditions such as Parkinson’s disease, Multiple Sclerosis and Alzheimer’s disease.


Michael Sember

Michael Sember

Chief Executive Officer

Michael Sember is an innovative entrepreneur with over 40 years’ experience in the life science and pharmaceutical industries, including extensive experience building and leading start-ups and global enterprises. In addition to being CEO of Regulonix, Michael is a Mentor-in-Residence at Tech Launch Arizona, assisting emerging University of Arizona life science companies with commercialization pathways, structure, business planning, financing and staffing.

A passionate leader who excels at creating, financing, and executing a company’s vision, Michael has served in senior leadership, EVP and business development roles at large multinational companies such as Marion Merrell Dow (now Sanofi Aventis) and Élan Corporation including overseeing investment activities, licensing deals, and partnering initiatives. He has also held CEO, President and Managing Director roles at start-up specialty pharmaceutical companies including leading several successful investments and turn-arounds. Active in the community, he serves on the board of Desert Angels, a Tucson-based group of accredited investors.

Michael earned his MBA from Rockhurst College in Kansas City, and obtained his BS in Psychology and Chemistry from the University of Pittsburgh.

Rajesh Khanna

Rajesh Khanna, PhD

Chief Scientific Officer

Dr. Rajesh Khanna, Professor of Pharmacology at the University of Arizona College of Medicine, is an expert in ion channel biology and voltage-gated calcium and sodium channels regulated by novel protein interaction. With almost 100 publications, Dr. Khanna’s ground-breaking research focuses on disrupting pathological protein-protein interactions with biologics and small molecules, testing their activity, examining protein interaction signatures, and regulating protein networks to modulate ion channel activity in neurodegenerative diseases (chronic pain, migraine, and neurofibromatosis).

Most recently Dr. Khanna’s lab has leveraged these pain network data discoveries to understand the mechanism of sodium and calcium channel trafficking by the CRMP2/NaV1.7 and CRMP2/CaV2.2 complex, the basis for the patented Regulonix technology platforms.

Dr. Khanna earned his PhD in Physiology from the University of Toronto, where he also obtained his MS in Pharmacology and a BS in Toxicology. Prior to joining the University of Arizona, he conducted post-doctoral fellowships at UCLA in Physiology and Molecular Biology, and at the Toronto Western Research Institute in Cellular and Molecular Biology. Additionally, he has received grant support from the NIH (NINDS, NIDA, NCI), the US Department of Defense, and the Children’s Tumor Foundation for his laboratory’s work, is a member of the Society of Neuroscience, American Society for Pain and the American Society for Neurochemistry and is a grant reviewer for several leading organizations worldwide.


Scientific Co-Founders

May Khanna, PhD

May Khanna, PhD

Vice-President & Director of Structural and Biophysical Chemistry

Vijay Gokhale, PhD

Vijay Gokhale, PhD

Director of Medicinal Chemistry


Advisory Board

Amol Patwardhan, MD, PhD

Director of Banner Health
University of Arizona Pain Clinic

Frank Porreca, PhD

Recipient of the 2016 IASP Ronald Melzack Lecture Award, and serves on scientific advisory boards of more than 10 biotechnology companies

Steven Arneric, PhD

Expert on ion channels in pain with over 25 years leading drug discovery campaigns in large pharmaceutical companies